Clinical trial
A Randomized, Open-label Phase III Clinical Trial Comparing Antivascular Therapy Combined With Standard Chemotherapy and Standard Chemotherapy in Adjuvant Therapy for Patients With Triple-Negative Breast Cancer, Basal-like Immunosuppressed Subtype (BCTOP-T-A03)
NCT05909332 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label Phase III Clinical Trial Comparing Antivascular Therapy Combined With Standard Chemotherapy and Standard Chemotherapy in Adjuvant Therapy for Patients With Triple-Negative Breast Cancer, Basal-like Immunosuppressed Subtype (BCTOP-T-A03)
- Lead sponsor
- Fudan University
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 20, 2023
- Completion date
- May 30, 2031
- Enrollment
- 764 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, triple negative breast cancer